Trevena (TRVN)
(Delayed Data from NSDQ)
$0.39 USD
-0.02 (-4.40%)
Updated Apr 26, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TRVN 0.39 -0.02(-4.40%)
Will TRVN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TRVN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRVN
Go Beyond Bargain Hunting; Buy 5 Stocks With Rising P/E
Aspira (AWH) Reports Q1 Loss, Tops Revenue Estimates
TRVN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aadi Bioscience, Inc. (AADI) Reports Q1 Loss, Tops Revenue Estimates
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
Trevena (TRVN) Initiates Proof-of-Concept for Epilepsy Candidate
Other News for TRVN
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
Buy Rating Affirmed on Trevena as Focus Shifts to Promising Drug Candidate TRV045
Buy Rating Affirmed for Trevena Amid Strategic Focus on Promising TRV045 Development